Floatz Rating
BB66/100
Confidence
Indicative
Sponsor
University Hospital, Gentofte, Copenhagen
Modality
protein_peptide
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
70High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06189001CT.gov The Role of Oxytocin-receptor Signalling in Physiological Regulation of Eating Behaviour in Individuals with Obesity | — | Completed | — | — | — |
NCT05289869CT.gov A Pilot Study: High Versus Low Oxytocin Dosing for Induction of Labor in Pregnant Patients With Obesity | — | Completed | — | — | — |
NCT04760496CT.gov Effect of Increased Oxytocin Doses on the Mode of Delivery in Obese Primiparous Women With Spontaneous or Induced Labour | — | Completed | — | — | — |
NCT05207774CT.gov Pre-operative Intranasal Oxytocin for Enhancing Bariatric-induced Diabetes Remission | — | Unknown | — | — | — |
NCT03957083CT.gov Oxytocin at Elective Cesarean Deliveries: A Dose-finding Study in Women With BMI ≥ 40kg/m2 | — | Completed | — | — | — |
NCT03497988CT.gov Intranasal Oxytocin and Food Intake in Obese Adolescents | — | Withdrawn | — | — | — |
NCT03119610CT.gov The Physiologic Effects of Intranasal Oxytocin on Sarcopenic Obesity | — | Completed | — | — | — |
NCT03043053CT.gov The Effects of Oxytocin in Obese Adults | — | Completed | — | — | — |
NCT03140488CT.gov Oxytocin Dosage to Decrease Induction Duration | — | Completed | — | — | — |
NCT02276677CT.gov Oxytocin Effects on Food Motivation Pathways | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
59High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Obesity Disorder
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Oxytocin (this asset) | University Hospital, Gentofte, Copenhagen | Approved | BB · 66 |
| vi-0521 | VIVUS LLC | P4 | BBB |
| Tirzepatide | Royal North Shore Hospital | P4 | BBB |
| asc30 | Ascletis Pharma (China) Co., Limited | P2 | BBB |
| Phentermine | Russell McCulloh, MD | P4 | BBB |
| Survodutide | Boehringer Ingelheim | P3 | BBB |
| Deoxycholic Acid | University of California, San Diego | P4 | BBB |
| Efsubaglutide Alfa | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | P4 | BBB |
| Cagrilintide | Novo Nordisk A/S | P3 | BBB |
+42 more in the Obesity Disorder cohort
Other indications for Oxytocin
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Prader-Willi Syndrome | — | P2/3 | BBB · 76 |
| Chronic Pain Syndrome | — | P4 | BB · 69 |
| Dystocia | — | P4 | BB · 67 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Oxytocin in Obesity Disorder. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/oxytocin-obesity-disorder
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →